Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7993654 | 0.78 | LMNA (0.41) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL25729132 | 0.75 | ERN1 (0.35) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL4597010 | 0.75 | GRIA1 (0.37) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL15873128 | 0.75 | TRIM24 (0.35) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL29790188 | 0.75 | TRIM24 (0.35) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL16333251 | 0.75 | TDP1 (0.42) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL10067118 | 0.75 | ERN1 (0.35) | ERN1LMNA | |
| SCHEMBL587088 | 0.75 | ERN1 (0.42) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL19794988 | 0.74 | LMNA (0.41) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL29411231 | 0.74 | LMNA (0.41) | ERN1TRIM24TRIM33LMNAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297210-B2 | Naphthyridine compounds and uses thereof | GENENTECH, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3826721-B1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-11 | — | — | EP | disclosed |
| EP-3826721-B1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20210277024-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3826721-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| CN-112533677-A | Naphthyridine compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020023551-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023551-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2651899-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ERN1 2368/4885TRIM24 4639/4885TRIM33 4710/4885 |
| US-12297210-B2 | Naphthyridine compounds and uses thereof | NEK1, NEK11, NEK5 | ERN1 263/4885TRIM24 2269/4885TRIM33 4233/4885 |
| US-20210277024-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | NEK1, NEK11, NEK5 | ERN1 266/4885TRIM24 2289/4885TRIM33 4277/4885 |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ERN1 2368/4885TRIM24 4639/4885TRIM33 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.